Last reviewed · How we verify

NCT05629078

Vision and Balance Changes After Bilateral Implantation of Toric IOLs

Status unknown NA Last updated 28 March 2024
What this trial tests

NA trial testing Toric intraocular lens Zeiss AT TORBI in Cataract Bilateral in 140 participants. Status unknown.

Timeline
12 January 2024
Primary endpoint
30 December 2024
31 July 2025

Quick facts

Lead sponsorUniversity of Plymouth
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment140
Start date12 January 2024
Primary completion30 December 2024
Estimated completion31 July 2025
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

University of Plymouth

Who can join

Adults 50 to 75, any sex, with Cataract Bilateral or Astigmatism Bilateral. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cataracts are the major cause of blindness in the world. Cataract surgery, being the most performed surgery in the world today, provide correction by extracting the natural lens from its capsular bag and replaced by an artificial intraocular lens (IOL) implantation. In the UK, almost all patients undergoing cataract surgery by the NHS are given monofocal intraocular lenses (IOLs) which do not correct corneal astigmatic error. It is estimated that around 20% of the population has over 1.50DC of corneal astigmatism. Uncorrected astigmatism not only increase spectacle dependency and reduce quality of life post surgically, but it also adversely affects the overall economic costs. Specialised toric IOLs offer the opportunity to correct pre-existing corneal astigmatism. Previous work has shown a link between reduced vision and balance or mobility. Full correction of refractive error may have greater impact on lifestyle than previously thought.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Human retinal secretome: A cross-link between mesenchymal and retinal cells.
    Donato L, Scimone C, Alibrandi S, Scalinci SZ, et al · · 2023 · cited 6× · PMID 37545752 · DOI 10.4252/wjsc.v15.i7.665

Verify or expand the search:

Other recruiting trials for Cataract Bilateral

Currently open trials in the same condition.

Other University of Plymouth trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05629078.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing